Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.25 GBX | +4.01% | +8.37% | +57.46% |
May. 01 | Poolbeg Pharma Secures Full Patent in US for Immunomodulator II | MT |
May. 01 | Poolbeg Pharma celebrates full patent approval for Immunomodulator II | AN |
Business Summary
Number of employees: 12
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 21-04-30 | |
Ian O'Connell
DFI | Director of Finance/CFO | 37 | 20-12-31 |
Carol Dalton
IRC | Investor Relations Contact | - | 20-12-31 |
Bruno Speder
LAW | General Counsel | - | 22-06-30 |
John McEvoy
LAW | General Counsel | 37 | Dec. 31 |
David Allmond
PRN | Corporate Officer/Principal | 54 | Nov. 30 |
Ross Crockett
AUD | Comptroller/Controller/Auditor | - | 21-05-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Luke O'Neill
BRD | Director/Board Member | 60 | - |
Chief Executive Officer | 53 | 21-04-30 | |
Cathal Friel
FOU | Founder | 59 | 20-08-31 |
Brendan Buckley
BRD | Director/Board Member | 73 | 23-05-23 |
Ian O'Connell
DFI | Director of Finance/CFO | 37 | 20-12-31 |
Eddie Gibson
BRD | Director/Board Member | 50 | 21-06-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 500,000,000 | 386,685,149 ( 77.34 %) | 0 | 77.34 % |
Company contact information
Poolbeg Pharma Plc
Queen Mary BioEnterprises Innovation Centre
E1 2AX, London
+
http://www.poolbegpharma.comSector
Sales per region
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+57.46% | 87.16M | |
+14.15% | 118B | |
+12.81% | 106B | |
-3.35% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-17.84% | 15.56B | |
+4.33% | 13.63B | |
+27.71% | 12.27B |
- Stock Market
- Equities
- POLB Stock
- Company Poolbeg Pharma PLC